@article{74bfae1f06c042e1969834eb704e6e37,
title = "Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies",
author = "Allan, {John N.} and Javier Pinilla-Ibarz and Gladstone, {Douglas E.} and Krish Patel and Sharman, {Jeff P.} and Wierda, {William G.} and Choi, {Michael Y.} and O'Brien, {Susan M.} and Mazyar Shadman and Davids, {Matthew S.} and Pagel, {John M.} and Yimer, {Habte A.} and Renee Ward and Gary Acton and Pietro Taverna and Combs, {Daniel L.} and Fox, {Judith A.} and Furman, {Richard R.} and Brown, {Jennifer R.}",
note = "Funding Information: Acknowledgments: medical writing support was provided by Janis Leonoudakis, PhD, and was funded by Sunesis Pharmaceuticals, Inc., San Francisco, CA. Funding: financial support for this study was provided by Sunesis Pharmaceuticals, Inc., South San Francisco, CA. Trial registration: clinicaltrials.gov Identifier: NCT03037645; EU clinical trials register identifier: EudraCT # 2018-000108-41",
year = "2022",
month = apr,
doi = "10.3324/haematol.2021.280061",
language = "English (US)",
volume = "107",
pages = "984--987",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",
}